✦ LIBER ✦

A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit

✍ Scribed by Brunetto, A T; Sarker, D; Papadatos-Pastos, D; Fehrmann, R; Kaye, S B; Johnston, S; Allen, M; De Bono, J S; Swanton, C

Book ID: 110000601
Publisher: Nature Publishing Group
Year: 2010
Tongue: English
Weight: 274 KB
Volume: 103
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6605812

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Oral Gossypol in the Treatment of Patien

Oral Gossypol in the Treatment of Patients with Refractory Metastatic Breast Cancer: A Phase I/II Clinical Trial

✍ Catherine Van Poznak; Andrew D. Seidman; Marcus M. Reidenberg; Mark M. Moasser; 📂 Article 📅 2001 🏛 Springer US 🌐 English ⚖ 180 KB

Phase II study of flutamide in patients

Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study

✍ Daniele J. Perrault; Diane M. Logan; David J. Stewart; Vivien H. C. Bramwell; Al 📂 Article 📅 1988 🏛 Springer US 🌐 English ⚖ 271 KB

The National Cancer Institute of Canada (NCIC) Clinical Trials Group conducted a phase II study of the oral antiandrogen flutamide in 33 patients with metastatic breast cancer. Eight patients had received no prior systemic therapy for their metastatic disease and 13 had only one site of metastasis.

Phase I trial of liposomal doxorubicin a

Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer

✍ Susana M. Campos; Suzanne T. Berlin; Leroy M. Parker; Wendy Y. Chen; Craig A. Bu 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 277 KB

The clinical benefit of pegylated liposo

The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial

✍ Al-Batran, S-E; Bischoff, J; von Minckwitz, G; Atmaca, A; Kleeberg, U; Meuthen, 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 130 KB

Heparin-induced thrombocytopenia with th

Heparin-induced thrombocytopenia with thrombosis: Incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution

✍ Nand, Sucha; Wong, Warren; Yuen, Benjamin; Yetter, Andrew; Schmulbach, Edwin; Gr 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 31 KB 👁 2 views

Heparin-induced thrombocytopenia with thrombosis (HITT) can lead to serious morbidity and may be potentially fatal. We reviewed our experience with this entity over a 4-year period, to determine the following: 1) incidence and type of thrombosis in patients with heparin-induced thrombocytopenia (HIT

Heparin-induced thrombocytopenia with th

Heparin-induced thrombocytopenia with thrombosis: Incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution

✍ Nand, S.; Wong, W.; Yuen, B.; Yetter, A.; Schmulbach, E.; Fisher, S.G. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 7 KB 👁 2 views

Cardiac events include angina, myocardial infarction, coronary angioplasty, coronary artery bypass grafting, and valvular surgery. b Miscellaneous events include trauma, carcinoma of the stomach, carcinoma of the prostate, cirrhosis of liver, renal failure, and scleroderma.